Nabriva shares tumble as safety worries plague pneumonia drug

(Reuters) - Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news